Principal Investigator
Peter Hosein
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20251062
Clinical Trial Summary
A Phase 2 trial of lorigerlimab (MGD019) in patients with pancreatic adenocarcinoma and homologous recombination deficiency
Phase
Phase II
Funding Agency/Sponsor
Institutional
Disease
Pancreatic, Liver, and Related Cancers
Contact Information
Phone Number
+1 (305) 2435004